Anti-idiotypic Patents (Class 424/131.1)
-
Publication number: 20140363422Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: January 2, 2013Publication date: December 11, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
-
Patent number: 8883148Abstract: A method for treating, preventing or reducing the risk of joint destruction in a subject who suffers from a joint or musculoskeletal disease. The method comprises administering a histone deacetylase (HDAC) inhibitor or in conjunction with other agents to inhibit degradation and resorption of cartilage and bone in the joint.Type: GrantFiled: March 14, 2005Date of Patent: November 11, 2014Assignee: ASAN Laboratories Company (Cayman), LimitedInventor: Yih-Lin Chung
-
Publication number: 20140328922Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicant: Selecta Biosciences, Inc.Inventor: Roberto A. Maldonado
-
Publication number: 20140322199Abstract: The technology described herein is directed to methods of treating cardiovascular and metabolic disorders.Type: ApplicationFiled: August 6, 2012Publication date: October 30, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Guo-Ping Shi
-
Patent number: 8846039Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.Type: GrantFiled: August 31, 2007Date of Patent: September 30, 2014Assignee: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20140271618Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: ApplicationFiled: October 10, 2012Publication date: September 18, 2014Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CCAM BIOTHERAPEUTICS LTD.Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
-
Publication number: 20140248211Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: INTENSITY THERAPEUTICS, INC.Inventor: Lewis H. Bender
-
Patent number: 8821874Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: July 22, 2013Date of Patent: September 2, 2014Assignee: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
-
Publication number: 20140242068Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.Type: ApplicationFiled: August 10, 2012Publication date: August 28, 2014Applicant: EMORY UNIVERSITYInventors: Charles A. Parkos, Dominique A. Weber
-
Publication number: 20140234294Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.Type: ApplicationFiled: December 24, 2013Publication date: August 21, 2014Applicant: Kobenhavns UniversitetInventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
-
Patent number: 8795669Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: July 27, 2012Date of Patent: August 5, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Scott Walsh, Daniel Dix
-
Publication number: 20140212408Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Applicant: ROCHE GLYCART AGInventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
-
Publication number: 20140178362Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.Type: ApplicationFiled: July 1, 2013Publication date: June 26, 2014Applicant: CELERA CORPORATIONInventors: Charles E. BIRSE, Bruno DOMON, Steve RUBEN, Candy LEE
-
Patent number: 8758753Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.Type: GrantFiled: March 19, 2009Date of Patent: June 24, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Publication number: 20140170134Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).Type: ApplicationFiled: August 15, 2012Publication date: June 19, 2014Applicant: The University of ChicagoInventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carta Emolo, Andrea Dedent
-
Patent number: 8753629Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: June 14, 2013Date of Patent: June 17, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20140161792Abstract: The present invention relates to a rhamno-polysaccharide antigen from Enterococcus faecium clonal complex which is useful as a vaccine component for therapy and/or prophylaxis of bacterial infection.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicants: FORSCHUNGSZENTRUM BORSTEL, UNIVERSIT TSKLINIKUM FREIBURGInventors: Johannes Hübner, Christian Theilacker, Zbignew Kacynski, Otto Holst
-
Publication number: 20140134155Abstract: The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.Type: ApplicationFiled: June 29, 2012Publication date: May 15, 2014Applicant: Technische Universität DresdenInventor: Michael Bachmann
-
Publication number: 20140134154Abstract: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.Type: ApplicationFiled: August 6, 2013Publication date: May 15, 2014Applicant: VANDERBILT UNIVERSITYInventors: Paula R. Pohlmann, Ray Mernaugh, Carlos Arteaga
-
Publication number: 20140127199Abstract: The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.Type: ApplicationFiled: November 24, 2010Publication date: May 8, 2014Applicant: The United States of America,as represented by the Secretary, Department of Health & Human ServicesInventors: Juan Rivera, Nicolas Charles
-
Publication number: 20140115729Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: ApplicationFiled: December 20, 2013Publication date: April 24, 2014Applicant: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Publication number: 20140065100Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
-
Publication number: 20140044702Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: ApplicationFiled: September 9, 2013Publication date: February 13, 2014Applicant: Genentech, Inc.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Publication number: 20140037615Abstract: The present invention relates to compositions, kits, and methods for preparing an autologous idiotype vaccine, or autologous anti-idiotype vaccine, for treatment of a B-cell malignancy based on the isotype(s) (class(es)) of immunoglobulins expressed by the malignancy; methods for treating B-cell malignancies; and methods for selecting a treatment for a subject having a B-cell malignancy.Type: ApplicationFiled: August 12, 2011Publication date: February 6, 2014Applicant: BIOVEST INTERNATIONAL, INC.Inventors: Carlos F. Santos, Mihaela Popa-Mckiver, Amy M. McCord, Mark Hirschel
-
Patent number: 8642039Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.Type: GrantFiled: December 21, 2010Date of Patent: February 4, 2014Assignee: KaloBios Pharmaceuticals, INc.Inventor: Geoffrey T. Yarranton
-
Patent number: 8637567Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.Type: GrantFiled: October 13, 2010Date of Patent: January 28, 2014Assignee: Neuren Pharmaceuticals Ltd.Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
-
Publication number: 20130330323Abstract: In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.Type: ApplicationFiled: August 31, 2011Publication date: December 12, 2013Inventors: Robert J. Dunn, Marilyn R. Kehry
-
Publication number: 20130315892Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.Type: ApplicationFiled: June 7, 2013Publication date: November 28, 2013Inventors: ALESSANDRO MORETTA, ROBERTA CASTRICONI, CHRISTINA BOTTINO, LORENZO MORETTA
-
Publication number: 20130302314Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: ApplicationFiled: May 7, 2013Publication date: November 14, 2013Inventor: Academia Sinica
-
Publication number: 20130302315Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: June 14, 2013Publication date: November 14, 2013Applicant: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20130243750Abstract: This invention provides anti-IgE antibodies that bind to the M1? segment of a human IgE and their use in treating and preventing IgE-mediated disorders, as well as kits comprising the anti-IgE antibodies.Type: ApplicationFiled: January 30, 2013Publication date: September 19, 2013Applicant: Genentech, Inc.Inventors: Heleen Scheerens, Jeffrey Mark Harris, John Matthews, Wendy Sue Putnam, X. Charlene Liao
-
Publication number: 20130243749Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: ApplicationFiled: June 2, 2011Publication date: September 19, 2013Applicant: Dana Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Patent number: 8501417Abstract: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.Type: GrantFiled: June 26, 2008Date of Patent: August 6, 2013Assignee: Vanderbilt UniversityInventors: Paula R. Pohlmann, Ray Mernaugh, Carlos Arteaga
-
Patent number: 8491905Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: June 28, 2012Date of Patent: July 23, 2013Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Publication number: 20130177624Abstract: Disclosed are methods for detecting an allergic lung disease that involve assessing the level of one or more microRNAs (miRNAs) in a biological sample, wherein the level of the one or more miRNAs in the biological sample compared to a reference level of the one or more miRNAs is indicative of allergic lung disease. Also disclosed are methods for the treatment or prevention of inflammatory or allergic lung disease that involve administration of a let-7 miRNA inhibitor as set forth herein, as well as biochips and kits that can be applied in the methods of the present invention.Type: ApplicationFiled: May 7, 2010Publication date: July 11, 2013Inventors: David Brian Corry, Farrah Kheradmand, Preethi Gunaratne, Sumanth Polikepahad, Arash Olyie Naghavi
-
Publication number: 20130156754Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.Type: ApplicationFiled: February 21, 2013Publication date: June 20, 2013Applicant: Xencor, Inc.Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
-
Publication number: 20130129715Abstract: Use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in therapeutic and contraceptive fields The present invention concerns the use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in tolerogenic or immunogenic form in the therapy for infertility or as contraceptive or post-coital interception means, respectively.Type: ApplicationFiled: July 13, 2011Publication date: May 23, 2013Inventors: Arcangelo Liso, Maria Matteo
-
Publication number: 20130129714Abstract: Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein.Type: ApplicationFiled: April 1, 2011Publication date: May 23, 2013Applicant: THE UAB RESEARCH FOUNDATIONInventor: Paul W. Sanders
-
Publication number: 20130121992Abstract: Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (GAD65) that is bound by antibody b96.11, and anti-idiotypic antibodies that are capable of competing with GAD65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of Type 1 diabetes and for inhibiting insulitis and other diabetic symptoms. Also provided are methods for detecting a susceptibility to Type 1 diabetes in a subject and for detecting the presence of anti-idiotypic antibodies to GAD65. The method comprises contacting a specimen with an antibody of the invention. The method further comprises detecting binding of the molecule to the specimen. The absence (or relative absence) of binding is indicative of susceptibility to Type 1 diabetes and of the absence of anti-idiotypic antibodies.Type: ApplicationFiled: January 14, 2013Publication date: May 16, 2013Applicant: UNIVERSITY OF WASHINGTONInventor: UNIVERSITY OF WASHINGTON
-
Patent number: 8431128Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: December 12, 2011Date of Patent: April 30, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
-
Patent number: 8426363Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.Type: GrantFiled: September 2, 2011Date of Patent: April 23, 2013Assignees: Rinat Neuroscience Corp., Pfizer Inc.Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Yuli Wang
-
Patent number: 8420090Abstract: Isolated and/or recombinant adhesin polypeptides from Burkholderia pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such polypeptides are also provided. Such antibodies can be used to detect the presence of B. pseudomallei or B. mallei and in methods of treating or preventing Burkholderia infection.Type: GrantFiled: October 4, 2011Date of Patent: April 16, 2013Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National DefenceInventors: Chad Wesley Stratilo, Scott James Jager
-
Publication number: 20130078234Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.Type: ApplicationFiled: April 24, 2012Publication date: March 28, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
-
Publication number: 20130071353Abstract: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.Type: ApplicationFiled: March 14, 2011Publication date: March 21, 2013Applicant: TRANA DISCOVERY, INCInventors: Richard H. Guenther, Jerzy R. Szewczyk
-
Patent number: 8367061Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.Type: GrantFiled: January 29, 2008Date of Patent: February 5, 2013Assignee: Pomona Ricera S.R.L.Inventors: Roberto Burioni, Massimo Clementi
-
Publication number: 20130028887Abstract: A compound represented by formula (I), wherein R1 represents a hydrogen atom, etc., R2 and R3 each independently represents a hydrogen atom, optionally oxidized C1-4 alkyl group or optionally protected hydroxyl group, or R2 and R3 taken together represent optionally oxidized C2-5 alkylene group, R4 represents an optionally oxidized C1-6 alkyl group, etc., R5 represents an optionally oxidized C1-6 alkyl group, etc., R6 represents an optionally oxidized C1-6 alkyl group, etc., m represents 0 or an integer from 1 to 3, n represents 0 or an integer from 1 to 4, and i represents 0 or an integer from 1 to 7.Type: ApplicationFiled: September 26, 2012Publication date: January 31, 2013Applicant: ONO PHARMACEUTICAL CO., LTD.Inventor: ONO PHARMACEUTICAL CO., LTD.
-
Publication number: 20120328615Abstract: This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.Type: ApplicationFiled: May 25, 2012Publication date: December 27, 2012Applicant: Innate Pharma SAInventors: Francois Romagne, Pascale Andre
-
Patent number: 8329169Abstract: The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that bind to and inhibit CD14 pathway components, such as CD14 and LPS. The invention also relates to methods of treating subjects suffering from sepsis comprising administering these compositions, as well as kits for supplying the compositions for treatment.Type: GrantFiled: May 14, 2004Date of Patent: December 11, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Tom Eirik Mollnes
-
Publication number: 20120294850Abstract: Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Inventors: Robert Yu, Seigo Usuki
-
Publication number: 20120294849Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Inventors: Mathias Brosz, FRIEDRICH WILHELM KUHNE, KLAUS BLASZKIEWITZ, THOMAS ISENSEE